Could the authors provide answers to the following questions:
1-How do you plan to address the limitations associated with the relatively small subgroup sizes, particularly for moderate and severe WMHs, in future studies to enhance statistical power?
2-Many of your significant findings did not pass FDR correction. Could you clarify how these results should be interpreted in terms of their robustness and potential clinical relevance?
3-Did you account for potential confounding variables, such as medication use, lifestyle factors, or other comorbidities, that might influence the dFNC metrics? If not, how might these factors have impacted the study’s outcomes?
4-While the study emphasizes the advantages of dynamic over static functional connectivity, what specific limitations of dFNC analysis did you encounter, and what steps did you take to mitigate these challenges?
5-The study identifies significant local efficiency variance (Eloc) but no notable differences in global efficiency (Eg). Could you elaborate on the potential physiological or methodological reasons for this discrepancy?